Tue, Jul 29, 2014, 3:49 PM EDT - U.S. Markets close in 11 mins.

Recent

% | $
Click the to save as a favorite.

Novadel Pharma Inc. Message Board

  • leonia5pbb leonia5pbb Feb 16, 2013 12:47 PM Flag

    "Duromist" can bring in many millions in NEW revenue for NVDL

    From a previous press report:

    "A ‘Viagra spray’ has passed through trials successfully."

    "Experts from NovaDel compared a spray form of sildenafil (the active ingredient in Viagra) to Viagra tablets themselves. Just two sprays of DuroMist were found to have similar effects to a 25mg Viagra pill."

    "But a Viagra spray could have many advantages over a tablet. Because a spray gets into the bloodstream quicker, sildenafil could work faster when applied this way, and it could also be more convenient and discreet for the user."

    Duromist so far as been shown to be very safe and very effective in clinical trials and could generate many millions of dollars in NEW revenue for NVDL in the future.
    Viagra in pill form has generated 2 billion dollars in total revenue since it was first marketed.
    It is only logical to assume that a "spray mist form of Viagra" can generate many millions of dollars in revenue.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • NovaDel Pharma Inc. Awarded $244,479 Grant from Qualifying

      NovaDel Pharma Inc. Awarded $244,479 Grant from Qualifying Therapeutic
      Discovery Project Program

      Business Wire

      BRIDGEWATER, N.J. -- November 03, 2010

      NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company
      developing oral spray formulations for a broad range of marketed
      pharmaceutical products, today announced that it has been awarded a $244,479
      grant under the IRS’ Qualifying Therapeutic Discovery Project, which it
      expects to receive in January 2011. The grant, which targets therapeutic
      discovery projects that show a reasonable potential to result in new therapies
      to treat areas of unmet medical need or to treat chronic or acute diseases and
      conditions or to result in reduced health care costs, was awarded to NovaDel
      to help fund the further clinical development of Duromist™. Duromist is
      NovaDel’s oral spray formulation of sildenafil, and is being developed for the
      treatment of erectile dysfunction.

      ”We are delighted that the potential advantages of Duromist have been
      recognized through the award of this grant,” commented Craig Johnson, Senior
      Vice President and CFO of NovaDel Pharma Inc.

      • 1 Reply to leonia5pbb
      • From a previous press report:

        "NovaDel Pharma Inc. has developed an oral spray formulation of sildenafil citrate that will be sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction. The Duromist™ dosage form is a metered spray that is administered orally and offers the potential for increased patient convenience, reduced food effect and lower dose. Earlier this year, NovaDel met with the FDA at a Pre-IND meeting to discuss its clinical plan for the New Drug Application (NDA). FDA has accepted the IND application and the required 30 day review period is now complete."

        “The filing of the IND represents an important milestone in the overall development plan for Duromist™,” commented Mr. Steven B. Ratoff, Chairman and Chief Executive Officer. “The opening of the IND will allow us to focus on completing the necessary studies and activities to support the NDA filing and approval.”

        "Duromist™ demonstrated an excellent safety profile and was well tolerated in this pilot PK study. There was no evidence of oral irritation and no adverse events were reported after administration of up to three doses of Duromist™. Vital signs were within normal range and there were no episodes of orthostatic hypotension observed in any of the four treatment periods. No changes were observed in the subjects' electrocardiograms in any of the four treatment periods."

        “These results are encouraging and demonstrate that greater bioavailability can be achieved with sildenafil administered as an oral spray form with the potential for a differentiated, patented Duromist™ product,” commented Mr. Steven B. Ratoff, NovaDel's Chairman of the Board, President & Chief Executive Officer. “This initial clinical study provides NovaDel with a solid foundation for our future clinical development efforts.”

        Other very important facts:

        1).. DUROMIST CAN GENERATE MANY MILLIONS OF DOLLARS IN NEW REVENUE FOR NVDL.

        2).. A PARTNERSHIP WITH ANOTHER PHARMA WOULD BE A WIN-WIN SITUATION TO CONTINUE WITH THE DUROMIST STUDY if there is a cash problem now with NVDL continuing the Duromist study another pharma can fund the study and share many millions of dollars in revenue from Duromist with NVDL.

        3)..Canada and China are only 2 countries that Duromist can be sold in, there are many other countries.

        4).. Viagra in pill form has generated more than 2 BILLION dollars since it was first marketed so why not Viagra in a spray which has many advantages over pill form?

        5).. Why pass up the opportunity of getting Duromist to the market to get many millions of dollars in revenue from it? Every month delayed is a substantial amount of money lost. It makes sense to do something right now with Duromist and NOT wait any longer.

        6)...Viagra patent loss in Canada is great news for Duromist.

 
NVDL
0.0090.000(0.00%)Jul 28 3:54 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.